Lipigon Pharmaceuticals AB (OSTO:LPGO) Net Change in Cash : kr14.47 Mil (TTM As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Lipigon Pharmaceuticals AB Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Lipigon Pharmaceuticals AB's Net Change in Cash for the three months ended in Dec. 2023 was kr-6.48 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2023 was kr14.47 Mil.

Lipigon Pharmaceuticals AB Net Change in Cash Historical Data

The historical data trend for Lipigon Pharmaceuticals AB's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lipigon Pharmaceuticals AB Net Change in Cash Chart

Lipigon Pharmaceuticals AB Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Change in Cash

Get a 7-Day Free Trial

0.94

11.51

15.92

-18.83

22.29

Lipigon Pharmaceuticals AB Quarterly Data
	Dec18	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Jun23	Sep23	Dec23
Net Change in Cash	Get a 7-Day Free Trial												-6.76	-5.94	13.04	7.91	-6.48

Lipigon Pharmaceuticals AB Net Change in Cash Calculation

Lipigon Pharmaceuticals AB's Net Change in Cash for the fiscal year that ended in Dec. 2023 is calculated as

Net Change in Cash	=	Cash Flow from Operations	+	Cash Flow from Investing	+	Cash Flow from Financing	+	Effect of Exchange Rate Changes
	=	-14.319	+	0	+	36.701	+	-0.091
	=	22.29

Lipigon Pharmaceuticals AB's Net Change in Cash for the quarter that ended in Dec. 2023

Net Change in Cash = Cash Flow from Operations + Cash Flow from Investing + Cash Flow from Financing + Effect of Exchange Rate Changes

= -6.48 + 0 + 0 + 0

= -6.48

Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was kr14.47 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lipigon Pharmaceuticals AB Net Change in Cash Related Terms
Thank you for viewing the detailed overview of Lipigon Pharmaceuticals AB's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Lipigon Pharmaceuticals AB (OSTO:LPGO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lipigon Pharmaceuticals AB (OSTO:LPGO) » Definitions » Net Change in Cash

Comparable Companies

OSTO:2CUREX XSAT:ABERA OSTO:EXPRS2 OSTO:SCOL XSAT:CHOSA OSTO:COMBI NGM:COEGIN XSAT:APTA XSAT:DBP B OSTO:CMOTEC B OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX

Traded in Other Exchanges

9RP:Germany

Address

Tvistevagen 48 C, Umea, SWE, 90736

Website

https://www.lipigon.se

Lipigon Pharmaceuticals AB develops medicines for diseases caused by disorders of the body's handling of fats. It focuses on orphan drugs for unusual diseases where there is no adequate treatment.

Lipigon Pharmaceuticals AB (OSTO:LPGO) Headlines

No Headlines